Published in Neurology on March 28, 2006
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology (2008) 3.62
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med (2011) 2.61
REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci (2010) 2.46
REM sleep behavior disorder: a possible early marker for synucleinopathies. Neurology (2006) 1.68
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci (2009) 1.34
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium (2010) 1.34
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep (2013) 1.30
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology (2010) 1.25
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience (2011) 1.20
The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal (2010) 1.16
Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology (2015) 1.13
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med (2009) 1.13
Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord (2011) 1.06
The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain (2013) 1.02
Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.98
Parasomnias: an updated review. Neurotherapeutics (2012) 0.98
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med (2013) 0.97
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Sleep in essential tremor: a comparison with normal controls and Parkinson's disease patients. Parkinsonism Relat Disord (2011) 0.94
REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep (2011) 0.93
REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging (2010) 0.93
Sleep disturbances associated with Parkinson's disease. Parkinsons Dis (2011) 0.90
Cardiac autonomic regulation during sleep in idiopathic REM sleep behavior disorder. Sleep (2007) 0.88
Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol (2013) 0.87
Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? J Neurol (2010) 0.87
Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. J Neurol (2014) 0.83
Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord (2016) 0.82
Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology (2017) 0.82
Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control. Neurol Sci (2012) 0.81
REM Sleep at its Core - Circuits, Neurotransmitters, and Pathophysiology. Front Neurol (2015) 0.81
Parkinson's disease and REM sleep behavior disorder result in increased non-motor symptoms. Sleep Med (2014) 0.80
Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study. J Clin Sleep Med (2015) 0.80
Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. J Neurol (2015) 0.80
Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. EPMA J (2011) 0.80
Investigation of autonomic function in idiopathic REM sleep behavior disorder. J Neurol (2011) 0.80
Lack of polysomnographic Non-REM sleep changes in early Parkinson's disease. Mov Disord (2013) 0.79
Odor Identification Test in Idiopathic REM-Behavior Disorder and Parkinson's Disease in China. PLoS One (2016) 0.79
Cognitive performances and mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder: results of a longitudinal follow-up study. Sleep (2013) 0.78
Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ (2006) 0.78
Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease. Brain (2016) 0.78
Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: A harbinger of freezing of gait? Mov Disord (2016) 0.77
Early diagnosis of Parkinson's disease. J Neurol (2006) 0.76
RBD and Neurodegenerative Diseases. Mol Neurobiol (2016) 0.76
Is there a need to redefine Parkinson's disease? J Neural Transm (Vienna) (2013) 0.76
Dysautonomia in narcolepsy: evidence by questionnaire assessment. J Clin Neurol (2014) 0.76
Subtle gait changes in patients with REM sleep behavior disorder. Mov Disord (2013) 0.76
Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism. Neuroepidemiology (2015) 0.75
Depressed REM Sleep Behavior Disorder Patients Are Less Likely to Recall Enacted Dreams than Non-Depressed Ones. Psychiatry Investig (2016) 0.75
Insomnia and somnolence in idiopathic RBD: a prospective cohort study. NPJ Parkinsons Dis (2017) 0.75
Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. Curr Psychiatry Rep (2017) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med (2004) 3.49
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Post-H1N1 narcolepsy-cataplexy. Sleep (2010) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol (2006) 2.11
A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep (2004) 2.03
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Precipitating factors of somnambulism: impact of sleep deprivation and forced arousals. Neurology (2008) 1.99
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet (2013) 1.55
Hypersynchronous delta waves and somnambulism: brain topography and effect of sleep deprivation. Sleep (2006) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Sleep following sport-related concussions. Sleep Med (2008) 1.52
Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology (2012) 1.52
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol (2009) 1.42
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42
Nocturnal breathing in cyanotic congenital heart disease. Int J Cardiol (2007) 1.41
Update on the pharmacology of REM sleep behavior disorder. Neurology (2006) 1.41
Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40
Short sleep duration and body mass index: a prospective longitudinal study in preadolescence. Am J Epidemiol (2011) 1.39
Electroencephalogram slowing in rapid eye movement sleep behavior disorder is associated with mild cognitive impairment. Sleep Med (2013) 1.39
Family history of idiopathic REM behavior disorder: a multicenter case-control study. Neurology (2013) 1.39
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep (2006) 1.37
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36